Melatonin attenuates (-)-epigallocatehin-3-gallate-triggered hepatotoxicity without compromising its downregulation of hepatic gluconeogenic and lipogenic genes in mice

Journal of Pineal Research

Volumn 59, Issue 4, 2015, Pages 497-507

  Wang, Dongxu ^a   Wei, Yaqing ^a   Wang, Taotao ^b   Wan, Xiaochun ^a   Yang, Chung S ^a,c   Reiter, Russel J ^d   Zhang, Jinsong ^a  

^a ANHUI AGRICULTURAL UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

^c RUTGERS UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

( ) Epigallocatehin 3 gallate; gluconeogenesis; hepatotoxicity; lipogenesis; melatonin

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE ALPHA; ACETYL COENZYME A CARBOXYLASE BETA; ACYL COENZYME A DESATURASE 1; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPIGALLOCATEHIN 3 GALLATE; FATTY ACID SYNTHASE; GALLIC ACID DERIVATIVE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE SYNTHASE; GLUTATHIONE TRANSFERASE M1; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; LEPTIN; MELATONIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; CATECHIN; EPIGALLOCATECHIN GALLATE; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; GLUCONEOGENESIS; LETHAL DOSE; LIPOGENESIS; LIVER FIBROSIS; LIVER NECROSIS; LIVER TOXICITY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SURVIVAL TIME; TOXIC DOSE; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; LIVER; METABOLISM;

ANIMALS; CATECHIN; FORKHEAD TRANSCRIPTION FACTORS; GLUCONEOGENESIS; LIPOGENESIS; LIVER; MALE; MELATONIN; MICE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84945964635     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12281     Document Type: Article

References (58)

1. Yany CS, Hong J,. Prevention of chronic diseases by tea: possible mechanisms and human relevance. Annu Rev Nutr 2013; 33: 161-181.
2. Khan N, Mukhtar H,. Tea and health: studies in humans. Curr Pharm Des 2013; 19: 6141-6147.
3. Wang S, Moustaid-Moussa N, Chen L, et al., Novel insights of dietary polyphenols and obesity. J Nutr Biochem 2014; 25: 1-18.
4. Bose M, Lambert JD, Ju J, et al., The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 2008; 138: 1677-1683.
5. Ortsäter H, Grankvist N, Wolfram S, et al., Diet supplementation with green tea extract epigallocatechin gallate prevents progression to glucose intolerance in db/db mice. Nutr Metab (Lond) 2012; 14: 9:11.
6. Sarma DN, Barrett ML, Chavez ML, et al., Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 2008; 31: 469-484.
7. Schönthal AH,. Adverse effects of concentrated green tea extracts. Mol Nutr Food Res 2011; 55: 874-885.
8. Mazzanti G, Menniti-Ippolito F, Moro PA, et al., Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009; 65: 331-341.
9. Wang D, Taylor EW, Wang Y, et al., Encapsulated nanoepigallocatechin-3-gallate and elemental selenium nanoparticles as paradigms for nanochemoprevention. Int J Nanomedicine 2012; 7: 1711-1721.
10. Klaus S, Pültz S, Thöne-Reineke C, et al., Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Int J Obes (Lond) 2005; 29: 615-623.
11. Pae M, Ren Z, Meydani M, et al., Dietary supplementation with high dose of epigallocatechin-3-gallate promotes inflammatory response in mice. J Nutr Biochem 2012; 23: 526-531.
12. Crew KD, Brown P, Greenlee H, et al., Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) 2012; 5: 1144-1154.
13. Shanafelt TD, Call TG, Zent CS, et al., Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 3808-3814.
14. Shanafelt TD, Call TG, Zent CS, et al., Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2013; 119: 363-370.
15. Acuña-Castroviejo D, Escames G, Venegas C, et al., Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014; 71: 2997-3025.
16. Reiter RJ, Tan DX, Rosales-Corral S, et al., The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem 2013; 13: 373-384.
17. Venegas C, García JA, Escames G, et al., Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res 2012; 52: 217-227.
18. Tan DX, Reiter RJ, Manchester LC, et al., Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2: 181-197.
19. García JJ, Lõpez-Pingarrõn L, Almeida-Souza P, et al., Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res 2014; 56: 225-237.
20. Romero A, Ramos E, de Los Ríos C, et al., A review of metal-catalyzed molecular damage: protection by melatonin. J Pineal Res 2014; 56: 343-370.
21. Manchester LC, Coto-Montes A, Boga JA, et al., Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res 2015; doi: 10.1111/jpi.12267. [Epub ahead of print].
22. Shen G, Xu C, Hu R, et al., Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Pharm Res 2005; 22: 1805-1820.
23. Zhang HM, Zhang Y,. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res 2014; 57: 131-146.
24. Wang D, Wang Y, Wan X, et al., Green tea polyphenol (-)-epigallocatechin-3-gallate triggered hepatotoxicity in mice: responses of major antioxidant enzymes and the Nrf2 rescue pathway. Toxicol Appl Pharmacol 2015; 283: 65-74.
25. Sang S, Lambert JD, Ho CT, et al., The chemistry and biotransformation of tea constituents. Pharmacol Res 2011; 64: 87-99.
26. Ishii T, Mori T, Tanaka T, et al., Covalent modification of proteins by green tea polyphenol (-)-epigallocatechin-3-gallate through autoxidation. Free Radic Biol Med 2008; 45: 1384-1394.
27. Rocchitta G, Migheli R, Esposito G, et al., Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease. J Pineal Res 2006; 40: 204-213.
28. Khaldy H, Escames G, Leõn J, et al., Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J Pineal Res 2000; 29: 100-107.
29. Miller JW, Selhub J, Joseph JA,. Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med 1996; 21: 241-249.
30. Tan DX, Manchester LC, Terron MP, et al., One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28-42.
31. Vriend J, Reiter RJ,. The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. Mol Cell Endocrinol 2015; 401: 213-220.
32. Vijayalaxmi, Meltz ML, Reiter RJ, et al., Melatonin and protection from whole-body irradiation: survival studies in mice. Mutat Res 1999; 425: 21-27.
33. Vijayalaxmi, Reiter RJ, Herman TS, et al., Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers. Mutat Res 1996; 371: 221-228.
34. Wu Q, Jing Y, Yuan X, et al., Melatonin treatment protects against acute spinal cord injury-induced disruption of blood spinal cord barrier in mice. J Mol Neurosci 2014; 54: 714-722.
35. Han J, Xu Y, Yu CX, et al., Melatonin reverses the expression of morphine-induced conditioned place preference through its receptors within central nervous system in mice. Eur J Pharmacol 2008; 594: 125-131.
36. Zhang BB, Zhou G, Li C,. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009; 9: 407-416.
37. Steinberg GR, Kemp BE,. AMPK in Health and Disease. Physiol Rev 2009; 89: 1025-1078.
38. Viollet B, Guigas B, Leclerc J, et al., AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 2009; 196: 81-98.
39. Viollet B, Foretz M, Guigas B, et al., Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006; 574: 41-53.
40. Collins QF, Liu HY, Pi J, et al., Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase. J Biol Chem 2007; 282: 30143-30149.
41. Murase T, Misawa K, Haramizu S, et al., Catechin-induced activation of the LKB1/AMP-activated protein kinase pathway. Biochem Pharmacol 2009; 78: 78-84.
42. Banerjee S, Ghoshal S, Porter TD,. Phosphorylation of hepatic AMP-activated protein kinase and liver kinase B1 is increased after a single oral dose of green tea extract to mice. Nutr Res 2012; 32: 985-990.
43. Serrano JC, Gonzalo-Benito H, Jové M, et al., Dietary intake of green tea polyphenols regulates insulin sensitivity with an increase in AMP-activated protein kinase α content and changes in mitochondrial respiratory complexes. Mol Nutr Food Res 2013; 57: 459-470.
44. Wolden-Hanson T, Mitton DR, Mccants RLY, et al., Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000; 141: 487-497.
45. Demirtas CY, Pasaoglu OT, Bircan FS, et al., The investigation of melatonin effect on liver antioxidant and oxidant levels in fructose-mediated metabolic syndrome model. Eur Rev Med Pharmacol Sci 2015; 19: 1915-1921.
46. Jiménez-Aranda A, Fernández-Vázquez G, Campos D, et al., Melatonin induces browning of inguinal white adipose tissue in Zucker diabetic fatty rats. J Pineal Res 2013; 55: 416-423.
47. Lardone PJ, Alvarez-Sanchez SN, Guerrero JM, et al., Melatonin and glucose metabolism: clinical relevance. Curr Pharm Des 2014; 20: 4841-4853.
48. Cipolla-Neto J, Amaral FG, Afeche SC, et al., Melatonin, energy metabolism, and obesity: a review. J Pineal Res 2014; 56: 371-381.
49. Tan DX, Hardeland R, Manchester LC, et al., Functional roles of melatonin in plants, and perspectives in nutritional and agricultural science. J Exp Bot 2012; 63: 577-597.
50. Arnao MB, Hernández-Ruiz J,. Functions of melatonin in plants: a review. J Pineal Res 2015; 59: 133-150.
51. Paredes SD, Korkmaz A, Manchester LC, et al., Phytomelatonin: a review. J Exp Bot 2009; 60: 57-69.
52. Reiter RJ, Tan DX, Zhou Z, et al., Phytomelatonin: assisting plants to survive and thrive. Molecules 2015; 20: 7396-7437.
53. Lissoni P, Barni S, Mandalàm M, et al., Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999; 35: 1688-1692.
54. Lissoni P, Chilelli M, Villa S, et al., Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 2003; 35: 12-15.
55. Wang YM, Jin BZ, Ai F, et al., The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 2012; 69: 1213-1220.
56. Cichoz-Lach H, Celinski K, Konturek PC, et al., The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis. J Physiol Pharmacol 2010; 61: 577-580.
57. Gonciarz M, Gonciarz Z, Bielanski W, et al., The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol 2012; 63: 35-40.
58. Celinski K, Konturek PC, Slomka M, et al., Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease-14 months follow up. J Physiol Pharmacol 2014; 65: 75-82.